

Giovanni FucÀ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3142460/publications.pdf>

Version: 2024-02-01

90
papers

2,556
citations

293460

24
h-index

263392

45
g-index

92
all docs

92
docs citations

92
times ranked

3991
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103532.	2.0	5
2	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. <i>Cancer Discovery</i> , 2022, 12, 90-107.	7.7	124
3	Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. <i>British Journal of Cancer</i> , 2022, 126, 449-455.	2.9	15
4	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 161, 90-98.	1.3	13
5	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with <i>RAS</i> Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	1.9	3
6	Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. , 2022, 10, e003897.		27
7	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
8	Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. <i>European Journal of Cancer</i> , 2022, 172, 300-310.	1.3	19
9	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. <i>Tumori</i> , 2021, 107, 353-359.	0.6	5
10	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021, 26, 302-309.	1.9	9
11	Development of a cure model for the estimation of long-term outcomes in patients with microsatellite instability(MSI)-high metastatic colorectal cancer (mCRC) receiving immune-checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2021, 39, 87-87.	0.8	0
12	Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. <i>Cancer Immunology Research</i> , 2021, 9, 441-453.	1.6	25
13	A combination of extracellular matrix and interferon-associated signatures identifies high-grade breast cancers with poor prognosis. <i>Molecular Oncology</i> , 2021, 15, 1345-1357.	2.1	6
14	Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy. <i>ESMO Open</i> , 2021, 6, 100046.	2.0	25
15	Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. <i>Cancers</i> , 2021, 13, 1453.	1.7	12
16	The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. <i>Cancers</i> , 2021, 13, 1964.	1.7	50
17	<i>EGFR</i> Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1561-1569.	3.0	12
18	Fully human antibody V _H domains to generate mono and bispecific CAR to target solid tumors. , 2021, 9, e002173.		8

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		18
20	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. Cytokine and Growth Factor Reviews, 2021, 59, 1-8.	3.2	4
21	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2021, 150, 155-167.	1.3	45
22	The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy. Targeted Oncology, 2021, 16, 529-536.	1.7	33
23	Author response to Colle et al. , 2021, 9, e003138.		0
24	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.		4
25	Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer. Cancers, 2021, 13, 3765.	1.7	7
26	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
27	Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nature Cancer, 2021, 2, 904-918.	5.7	60
28	Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. Oncologist, 2021, 26, 1079-1084.	1.9	5
29	Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors. Melanoma Research, 2021, 31, 178-180.	0.6	4
30	A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor. Cancer Immunology Research, 2020, 8, 57-69.	1.6	11
31	The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases. Scientific Reports, 2020, 10, 10871.	1.6	10
32	Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers. Clinical Sarcoma Research, 2020, 10, 17.	2.3	5
33	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Oncologist, 2020, 25, 803-809.	1.9	26
34	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. British Journal of Cancer, 2020, 123, 403-409.	2.9	93
35	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Clinical Colorectal Cancer, 2020, 19, 219-225.	1.0	45
36	Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. Clinical Cancer Research, 2020, 26, 5534-5538.	3.2	15

#	ARTICLE	IF	CITATIONS
37	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. <i>Oncologist</i> , 2020, 25, e460-e468.	1.9	29
38	Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2444-2451.	3.2	94
39	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. <i>International Journal of Cancer</i> , 2020, 147, 2303-2315.	2.3	14
40	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020, 25, 780-786.	1.9	14
41	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024.	3.2	22
42	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 3099-3110.	0.8	65
43	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3392-3400.	0.8	293
44	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. <i>Scientific Reports</i> , 2019, 9, 12993.	1.6	21
45	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , 2019, 19, 465-472.	0.9	16
46	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). <i>Clinical Cancer Research</i> , 2019, 25, 5295-5300.	3.2	70
47	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019, 97, 38-43.	0.9	26
48	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2858.	1.6	38
49	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019, 9, 3545.	1.6	22
50	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 72-78.	0.9	54
51	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	2.0	151
52	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019, 4, e000489.	2.0	14
53	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019, 24, e536-e541.	1.9	26
54	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	1

#	ARTICLE	IF	CITATIONS
55	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , 2019, 107, 164-174.	1.3	9
56	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	1.0	7
57	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019, 144, 1704-1712.	2.3	20
58	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 66-66.	0.8	17
59	Fumarate hydratase expression in localized, radically-resected clear cell renal cell carcinoma and its association with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 620-620.	0.8	0
60	Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e735-e742.	0.9	14
61	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. <i>Annals of Oncology</i> , 2018, 29, 1394-1401.	0.6	72
62	Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features. <i>Oncology</i> , 2018, 94, 1-6.	0.9	8
63	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	3.2	76
64	Immunotherapy-based combinations: an update. <i>Current Opinion in Oncology</i> , 2018, 30, 345-351.	1.1	25
65	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Targeted Oncology</i> , 2018, 13, 795-800.	1.7	15
66	TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery. <i>Tumori</i> , 2018, 104, 401-405.	0.6	10
67	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018, 95, 344-352.	0.9	11
68	Abstract B022: Metabolic and immunologic effects of the fasting mimicking diet in cancer patients. , 2018, , .		2
69	Safety and metabolic effects of cyclic fasting mimicking diet (FMD) in cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14549-e14549.	0.8	2
70	Effects of cabozantinib on bone turnover markers in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 638-638.	0.8	1
71	Prognostic and predictive role of fumarate hydratase in metastatic clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 617-617.	0.8	0
72	A phase 2 study of cabozantinib as first-line treatment in collecting ducts renal cell carcinoma: The BONSAI trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS709-TPS709.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Impact of pathological stratification of advanced well differentiated/dedifferentiated (WD/DD) liposarcoma (LPS) on the response to trabectedin (T).. Journal of Clinical Oncology, 2018, 36, 11566-11566.	0.8	1
74	Abstract CT095: Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation. , 2018, , .		3
75	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	183
76	Multimodal treatment of advanced renal cancer in 2017. Expert Review of Clinical Pharmacology, 2017, 10, 1395-1402.	1.3	23
77	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING caseâ€“control study. Annals of Oncology, 2017, 28, 3009-3014.	0.6	72
78	Castration-naïve metastatic prostate cancer: reshaping old paradigms. Expert Review of Anticancer Therapy, 2017, 17, 879-881.	1.1	3
79	Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. Oncology, 2017, 93, 279-286.	0.9	9
80	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. ESMO Open, 2017, 2, e000241.	2.0	10
81	RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC). Annals of Oncology, 2017, 28, iii140-iii141.	0.6	0
82	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. British Journal of Cancer, 2017, 117, 347-352.	2.9	31
83	Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study. Gynecologic Oncology, 2017, 144, 90-95.	0.6	73
84	Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 208, 41-45.	0.5	12
85	Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT. Annals of Oncology, 2017, 28, iii95.	0.6	0
86	Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT.. Journal of Clinical Oncology, 2017, 35, 11601-11601.	0.8	1
87	Identification and characterization of a novel <i>SCYL3-NTRK1</i> rearrangement in a colorectal cancer patient. Oncotarget, 2017, 8, 55353-55360.	0.8	33
88	Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements.. Journal of Clinical Oncology, 2017, 35, 589-589.	0.8	0
89	Abstract LB-238: Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) inRASandBRAFWild-type (wt) metastatic colorectal cancer (mCRC). , 2017, , .		0
90	Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis. Gynecologic Oncology, 2016, 143, 443-447.	0.6	44